Biogen (BIIB) reported 3rd Quarter September 2018 earnings of $7.40 per share on revenue of $3.4 billion. The consensus earnings estimate was $6.80 per share on revenue of $3.3 billion. The Earnings Whisper number was $6.91 per share. Revenue grew 11.7% on a year-over-year basis.
Biogen Idec Inc, is a biopharmaceutical company. The Company discovers,
develops, manufactures and markets therapies for neurological, autoimmune and hematologic disorders.